Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
ST266 is a cell-free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels. Extensive preclinical studies have shown that ST266’s multiple components result in a variety of anti-inflammatory and neuroprotective responses.
Lead Product(s): ST266
Therapeutic Area: Gastroenterology Product Name: ST266
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
OSSM-001, a mesenchymal stem cell (MSC) product is the second Ossium cell therapy product to enter the clinic, for the treatment of refractory perianal fistulas in patients with Crohn’s disease.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Gastroenterology Product Name: OSSM-001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Preclinical data from in vitro and in vivo experiments showing that OQL051, a gut-restricted CDK4/6 inhibitor, had significant efficacy in protecting gastrointestinal tissues from damage and decreasing diarrhea caused by chemotherapy for prevention of CID.
Lead Product(s): OQL051
Therapeutic Area: Gastroenterology Product Name: OQL051
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Ventyx’s pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome.
Lead Product(s): VTX002
Therapeutic Area: Gastroenterology Product Name: VTX002
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $151.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 21, 2021
Details:
Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
Lead Product(s): GT-2108
Therapeutic Area: Gastroenterology Product Name: GT-2108
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Financing June 30, 2021
Details:
The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.
Lead Product(s): GT-2108
Therapeutic Area: Gastroenterology Product Name: GT-2108
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 19, 2021
Details:
PPD will manage the Phase 1b/2a clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, also known as FW-420.
Lead Product(s): Niclosamide
Therapeutic Area: Gastroenterology Product Name: FW-420
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2021
Details:
MIT-001 is an anti-inflammatory and anti-necrotic agent, specifically scavenging ROS in the mitochondria. MitoImmune plans to initiates a Phase 2 trial of oral mucositis (OM) prevention and is expanding OM treatment into hematopoietic stem cell transplantation.
Lead Product(s): MIT-001
Therapeutic Area: Gastroenterology Product Name: MIT-001
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2021
Details:
Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline, including funding continued patient enrollment for the pivotal Phase 3 trial of Mytesi for prophylaxis of diarrhea in adult cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 23, 2020
Details:
The capital raised will enable to advance the clinical development of its lead antibody program targeting TL1A-associated IBD and grow its emerging pipeline of precision medicine programs designed to deliver life-changing outcomes for patients.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 09, 2020
